Format

Send to

Choose Destination
Future Oncol. 2019 Aug;15(24s):13-19. doi: 10.2217/fon-2019-0099. Epub 2019 Aug 6.

Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma.

Author information

1
Endocrinology Unit, Policlinico San Martino, Genoa, 16132, Italy.
2
Pathology, Department of Integrated Surgical & Diagnostic Sciences, University of Genoa, Genoa, 16132, Italy.
3
Pathology Unit, Policlinico San Martino, Genoa, 16132, Italy.
4
Endocrine Surgery Unit, Policlinico San Martino, Genoa, 16132, Italy.
5
Endocrine Unit, Thyroid GIP at the Policlinico Hospital San Martino, Genoa, 16132, Italy.
6
Endocrine Surgery Unit, Thyroid GIP at the Policlinico Hospital San Martino, Genoa, 16132, Italy.
7
Cyto-Histopathological Unit and Pathology Unit, Thyroid GIP at the Policlinico Hospital San Martino, Genoa, 16132, Italy.
8
Nuclear Medicine Unit, Thyroid GIP at the Policlinico Hospital San Martino, Genoa, 16132, Italy.

Abstract

We report a case of an elderly woman presenting with a huge cervical mass invading the tracheal lumen. Diagnosed as invasive poorly differentiated thyroid cancer, after an endotracheal biopsy, stenting and radiotherapy, it was judged eligible for total thyroidectomy, but surgery was delayed due to pulmonary thromboembolism. The patient was therefore treated with lenvatinib with a neoadjuvant intent until hemodynamic stability was obtained. Thyroidectomy and radioiodine therapy were then performed and the postdose scan revealed an area of modest uptake in the anterior part of the neck. The patient is now in a good clinical status and she continues her follow-up program without any adjuvant therapy.

KEYWORDS:

case report; lenvatinib; neoadjuvant; thyroid carcinoma

PMID:
31385546
DOI:
10.2217/fon-2019-0099
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center